Back to top
more

Clearside Biomedical (CLSD)

(Delayed Data from NSDQ)

$0.41 USD

0.41
430,893

+0.02 (6.40%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $0.41 0.00 (0.59%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

QIAGEN (QGEN) Launches QIAcube Connect MDx Platform Globally

by Zacks Equity Research

QIAGEN's (QGEN) QIAcube Connect MDx platform can be used with more than 140 standard protocols and it ensures complete consistency of the purification of multiple sample types.

Zacks Equity Research

Medtronic's (MDT) HVAD Pump Kit Recall Classified as Class I

by Zacks Equity Research

The latest back-to-back incidents will, undoubtedly, create a major drag in Medtronic's (MDT) VAD performance.

Zacks Equity Research

Bayer's (BAYRY) Q4 Earnings Match Estimates, Sales Miss

by Zacks Equity Research

Bayer (BAYRY) reports in-line earnings and misses sales estimates in the fourth quarter of 2020.

Zacks Equity Research

Horizon's (HZNP) Shares Rise on Q4 Earnings & Sales Beat

by Zacks Equity Research

Horizon (HZNP) beats earnings and sales estimates in the fourth quarter of 2020.

Zacks Equity Research

bluebird (BLUE) Q4 Loss Narrower than Expected, Sales Miss

by Zacks Equity Research

bluebird (BLUE) reports a narrower-than-expected loss but misses sales estimates in the fourth quarter of 2020.

Zacks Equity Research

Seagen (SGEN), Astellas Submit 2 sBLAs to FDA for Urothelial Cancer

by Zacks Equity Research

Seagen (SGEN) and Astellas Pharma announced completion of submissions of two sBLAs to the FDA for Padcev in patients with locally advanced or metastatic urothelial carcinoma.

Zacks Equity Research

bluebird (BLUE) Down on Suspension of Sickle Cell Disease Studies

by Zacks Equity Research

bluebird (BLUE) temporarily suspends two studies of LentiGlobin gene therapy in SCD because of reported Suspected Unexpected Serious Adverse Reactions of acute myeloid leukemia.

Zacks Equity Research

What's in the Cards for Arcturus (ARCT) This Earnings Season?

by Zacks Equity Research

Arcturus (ARCT) is likely to discuss the progress of its COVID-19 vaccine candidate on the fourth-quarter earnings call.

Zacks Equity Research

Zoetis' (ZTS) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis (ZTS) beats both earnings and sales estimates in the fourth quarter of 2020.

Zacks Equity Research

What's in the Cards for Sarepta (SRPT) This Earnings Season?

by Zacks Equity Research

Sarepta Therapeutics' (SRPT) fourth-quarter results are expected to reflect the ongoing COVID-19 impact. Launch plans for casimersen is what investors are expected be focused on.

Zacks Equity Research

Clearside Biomedical's (CLSD) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Clearside Biomedical (CLSD).

Zacks Equity Research

AzurRx (AZRX) Starts Dosing in Pancreatic Insufficiency Study

by Zacks Equity Research

AzurRX (AZRX) is developing its pipeline candidate, MS1819, as monotherapy as well in combination with standard of care for treating exocrine pancreatic insufficiency in patients with cystic fibrosis.

Zacks Equity Research

Implied Volatility Surging for Clearside Biomedical (CLSD) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Clearside Biomedical (CLSD) stock based on the movements in the options market lately.

Zacks Equity Research

Are You Looking for a Top Momentum Pick? Why Clearside Biomedical, Inc. (CLSD) is a Great Choice

by Zacks Equity Research

Does Clearside Biomedical, Inc. (CLSD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Clearside Biomedical (CLSD) Enters Oversold Territory

by Zacks Equity Research

Clearside Biomedical (CLSD) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 0.00% and -75.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Clearside Biomedical Inc (CLSD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Clearside Biomedical Inc (CLSD) delivered earnings and revenue surprises of 22.22% and 2.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -75.00% and -67.06%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will Clearside Biomedical Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Clearside Biomedical.

Sweta Killa headshot

Biotech Leading in Q4: Best ETFs & Stocks

by Sweta Killa

We highlight five biotech ETFs and stocks that are leading the market in Q4.